Royal Bank Of Canada Invitae Corp Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.42 - $0.72 $7,483 - $12,828	17,817 Added 43.17%	59,092 $37,000
Q3 2023 Nov 14, 2023	BUY	$0.6 - $1.53 $5,382 - $13,725	8,971 Added 27.77%	41,275 $24,000
Q2 2023 Aug 14, 2023	BUY	$1.05 - $1.63 $11,267 - $17,491	10,731 Added 49.74%	32,304 $36,000
Q1 2023 May 15, 2023	SELL	$1.2 - $2.73 $29,900 - $68,023	-24,917 Reduced 53.6%	21,573 $29,000
Q4 2022 Feb 14, 2023	BUY	$1.71 - $3.61 $14,671 - $30,973	8,580 Added 22.63%	46,490 $86,000
Q3 2022 Nov 14, 2022	SELL	$1.9 - $8.63 $14,880 - $67,590	-7,832 Reduced 17.12%	37,910 $93,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $9.01 $146,963 - $621,662	-68,997 Reduced 60.13%	45,742 $111,000
Q1 2022 May 16, 2022	SELL	$6.28 - $15.59 $100,574 - $249,673	-16,015 Reduced 12.25%	114,739 $914,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $28.67 $678,493 - $1.32 Million	-46,156 Reduced 26.09%	130,754 $2 Million
Q3 2021 Nov 15, 2021	BUY	$24.31 - $33.6 $228,441 - $315,739	9,397 Added 5.61%	176,910 $5.03 Million
Q2 2021 Aug 16, 2021	BUY	$26.09 - $40.4 $4.37 Million - $6.77 Million	167,513 New	167,513 $5.65 Million

2.12M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.